Benefits
Joint Pain and Mobility (Clinical Evidence)
Multiple RCTs of Devil's Claw extracts (including Flexigo-grade) show pain reduction and improved mobility in osteoarthritis. Chrubasik 2003 systematic review confirmed efficacy. Effect comparable to non-pharmaceutical alternatives.
Inflammation Marker Reduction
Devil's Claw extracts modulate inflammatory pathways; reduce inflammation markers in some trials. Mechanism: harpagoside and other iridoid compounds inhibit COX-2, lipoxygenase, NF-κB pathway.
EFSA Pending Claims
Two pending EFSA claims for Harpagophytum procumbens: (1) 'Helps to maintain joint health'; (2) 'Helps to maintain flexible joints and good mobility'. Pending status; reflects substantial evidence base for joint applications.
Athletic Application
Useful for active people and athletes with joint stress — supports recovery and ongoing joint comfort with intense use. Adjunct to comprehensive joint care.
Carrier-Free 100% Active Ingredient
Flexigo™ is 100% Devil's Claw (no carrier); allows precise dosing and high active concentration. Distinguishes from products diluted with maltodextrin or other fillers.
Mechanism of action
Harpagoside Anti-Inflammatory Activity
Harpagoside (and harpagide, procumbide) are iridoid glycosides — primary actives. Inhibit COX-2, lipoxygenase pathway, NF-κB activation. Mechanism similar in direction to NSAIDs but weaker effect; better tolerability.
Cytokine Modulation
Reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6); contributes to joint inflammation reduction.
Cartilage Protection (Theoretical)
Some animal evidence for chondroprotective effects — protection of cartilage from inflammatory degradation. Clinical translation incomplete.
Sustainable Wild-Harvest Sourcing
Devil's Claw grows wild in Southern Africa (Namibia, Botswana, South Africa); roots harvested sustainably with rotation systems. Nexira maintains long-term sustainable supply chain partnerships.
Clinical trials
Systematic review of Devil's Claw RCTs for arthritis pain.
Pooled across multiple osteoarthritis trials.
Significant evidence for pain reduction and mobility improvement vs placebo. Effect comparable to other natural anti-inflammatory approaches. Established Devil's Claw as evidence-based joint health intervention.
Studies comparing Devil's Claw extracts to NSAIDs for joint pain.
Osteoarthritis patients.
Devil's Claw less effective than NSAIDs but better tolerated; reasonable adjunct or alternative for those needing chronic joint support without NSAID GI/cardiovascular risks.
About this ingredient
FLEXIGO™ is a STANDARDIZED DEVIL'S CLAW EXTRACT (HARPAGOPHYTUM PROCUMBENS and Harpagophytum zeyheri) developed by NEXIRA (France). DEVIL'S CLAW BOTANY: native to SOUTHERN AFRICA (especially Namibia, Botswana, South Africa Kalahari Desert region); plant produces distinctive hooked fruits ('claws') that snag on passing animals; medicinal part is the SECONDARY ROOT (different from primary tap root). Used in TRADITIONAL SOUTHERN AFRICAN MEDICINE for centuries; introduced to European medicine in 1900s; modern therapeutic use established.
KEY ACTIVE: HARPAGOSIDE — iridoid glycoside; primary anti-inflammatory compound; HARPAGIDE and PROCUMBIDE are minor related compounds. FLEXIGO™ DISTINCTIONS: (1) STANDARDIZED HARPAGOSIDE CONTENT — up to 20% (HPLC method) — among highest in industry; (2) 100% DEVIL'S CLAW — carrier-free; (3) SUSTAINABLE SOURCING from Southern African partnerships; (4) ORGANIC GRADE AVAILABLE; (5) ROOTS picked sustainably, transported and processed in France with gentle water extraction and physical concentration.
EVIDENCE-BASED USES: (1) JOINT PAIN AND MOBILITY (Chrubasik 2003); (2) Osteoarthritis adjunct; (3) Athletic joint support; (4) Anti-inflammatory adjunct; (5) Pending EFSA claims for joint health.
CRITICAL CAUTIONS: (1) PREGNANCY — Devil's Claw has historical UTEROTONIC effects; AVOID supplementation in pregnancy; (2) GASTRIC ULCERS / SEVERE GERD — may stimulate gastric acid secretion; AVOID with active ulcer disease or severe GERD; (3) ANTICOAGULANTS — theoretical bleeding risk; consult prescriber; modest at typical doses; (4) DIABETES MEDICATIONS — modest hypoglycemic effects; monitor; (5) DOSE — 1.8-3 g/day extract; depends on harpagoside standardization; product specifies recommended dosing; (6) DURATION — joint effects build over 4-12 weeks; not immediate; (7) STANDARDIZATION VARIATION — Devil's Claw products vary widely (1-30% harpagosides); higher standardization allows lower volume; verify product specification; (8) DEVIL'S CLAW VS GLUCOSAMINE/CHONDROITIN/SAM-e — different mechanisms; reasonable to combine for comprehensive joint support; (9) DEVIL'S CLAW VS NSAIDs — Devil's Claw less effective but better tolerated for chronic use; reasonable for those needing long-term joint support without NSAID side effects; (10) SUSTAINABLE HARVESTING — wild-harvested with rotation systems; community-based sourcing supports rural African economies; verify sustainability certifications; (11) APPLICATIONS — capsules, tablets, sticks; (12) ATHLETIC USE — for active people experiencing joint stress; modest effect; (13) ELDERLY OSTEOARTHRITIS — well-tolerated for chronic use; reasonable component of integrative joint care; (14) BRAND VERIFICATION — Flexigo™ is Nexira trademark; specific clinical evidence and sustainability on this standardized form.